
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics is strategically focusing its resources on the development of promising therapeutics, specifically the HER3-targeting ADC, EO-1022, which positions the company to capitalize on opportunities within the evolving biotechnology sector. The management's decision to execute a workforce reduction reflects a commitment to financial prudence, aiming to streamline operations amid a challenging financial environment. Despite recent adjustments to revenue projections and an increase in the discount rate, the long-term potential of ELVN-001 and ELVN-002 underscores a positive outlook for the company's growth trajectory in treating significant oncogenic drivers in oncology.
Bears say
Enliven Therapeutics recently decided to discontinue the development of its Claudin 18.2-targeting ADC, EO-3021, due to disappointing efficacy results in its ongoing Phase 1 study. Although the drug has demonstrated tolerability, its low efficacy raises concerns regarding its viability as an independent therapeutic option and diminishes prospects for future investment. Consequently, this combination of halted drug development and reduced expectations reflects a challenging outlook for Enliven Therapeutics's financial position and future growth potential.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares